Mechanistically, ERK5 inhibition of EC cells resulted in impairment of EGF-induced c-Jun expression and AP-1 transcriptional activity, as reported for other ERK5i in cancer types, such as breast cancer [39] and hepatocellular carcinoma [36]. Here, EGF is linked to breast cancer.